Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Post by Rarbar99on Sep 30, 2021 10:06am
137 Views
Post# 33943031

This is what Pez said on June 17

This is what Pez said on June 17

This is what Pez said to Yukon on June 17, a month before the crash. He said "entry is low enough" and "the science cannot be denied"

this was back when ATE was close to $4 

And he still has the nerve to show his face here and spew his BS opinions.

Inthepez wrote: We should be above $10 easily. Biggest drawback to ATE is not uplisting to the Nasdaq. Everyone go message antibe about this. At the end of the day, the science can’t be denied. Companies take 1 step forward and 2 back, and still end up on top. Some don’t. Do your own risk assessment. But entry is low enough that I don’t give af. 

 

Inthepez wrote: You missed the point fud fairy. I’m not forecasting. Don’t get caught with your pants down like with the nuance deal. Rumours are going around. 

Go go back to fishing. Hopefully you don’t come back. 

 

YukonJezza wrote:
after giving me grief. Your classic buddy

 

 




 

<< Previous
Bullboard Posts
Next >>